Conjugated Estrogen Vaginal Premarin Cream 14gm - Cream Conjugated Oestrogens - 14gm 1 14gm tube(s) / 14gm tube Pfizer Introduction: Conjugated Estrogen Vaginal Premarin Cream 14gm is a female sex hormone (estrogen). It is a part of female hormonal replacement therapy which helps in treating estrogen deficiency symptoms like hot flushes (red and warm face) and vaginal dryness. Conjugated Estrogen Vaginal Premarin Cream 14gm is also used to prevent osteoporosis (thinning and weakening of bone) in postmenopausal women, who are at high risk of fractures and can not take other preventive medicines for osteoporosis. It can be taken with or without food, but remember to take it at a fixed time each day for better efficacy. The dose and duration... Uses of Conjugated Estrogen Vaginal Premarin Cream 14gm: Hormone replacement therapy Side effects of Conjugated Estrogen Vaginal Premarin Cream 14gm: BloatingBreast painHair lossHeadacheIrregular vaginal bleedingNauseaStomach crampVomiting How to use Conjugated Estrogen Vaginal Premarin Cream 14gm: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Conjugated Estrogen Vaginal Premarin Cream 14gm may be taken with or without food, but it is better to take it at a fixed time. How Conjugated Estrogen Vaginal Premarin Cream 14gm works: Conjugated Estrogen Vaginal Premarin Cream 14gm is a mixture of estrogens (female sex hormone). In women who are undergoing or have attained menopause, it prevents symptoms such as hot flushes, night sweats and mood swings. It also prevents the bones from becoming porous and fragile (osteoporosis). What if you forget to take Conjugated Estrogen Vaginal Premarin Cream 14gm?: If you miss a dose of Conjugated Estrogen Vaginal Premarin Cream 14gm, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose. Indication: Osteoporosis, Fungal infections, Itching, Burning, Hot flashes, Vaginal dryness, Vaginal atrophy, Menopausal symptoms, Female hypogonadism, Metastatic breast carcinoma, Ovarian failure, Prostate carcinoma, Primary ovarian failure, Hormone replacement therapy, Oral contraceptives Adult Dose: Menopausal Vasomotor Symptoms, Atrophic Vaginitis/Kraurosis Vulvae 0.3 mg PO once daily in either continuous daily regimen or cyclic regimen (25 days on, 5 days off); adjusted PRN; use lowest dose that control symptoms; may be given daily if medical assessment warrants it Female Hypogonadism 0.3-0.625 mg PO once daily in cyclic regimen (3 weeks on, 1 week off); may be titrated every 6-12 months; adjusted PRN; add progestin treatment should be added to maintain bone mineral density once skeletal maturity achieved Osteoporosis Prophylaxis 0.3 mg PO once daily in cyclic regimen (25 days on, 5 days off); adjusted PRN based... Contraindication: Severe liver impairment; breast carcinoma; thromboembolic disorders; CV disease; undiagnosed vag bleeding; estrogen-dependent neoplasms; hypersensitivity; pregnancy. Mode of Action: Estrogens modulate pituitary secretion of gonadotropins, leutinising hormones and follicle-stimulating hormones through -ve feedback mechanism, thus reducing elevated levels of hormones in postmenopausal women during oestrogen replacement therapy. Precaution: Asthma, epilepsy, migraine; heart or kidney dysfunction; CV disease; cerebrovascular disorders; diabetes, hypercalcaemia; gall bladder disease; porphyria. Childn. Lactation. Lactation: Use controversial; estrogens are excreted into breast milk in small quantities; use with caution Side Effect: >10% Abdominal pain (15-17%),Back pain (13-14%),Breast enlargement,Breast tenderness (7-12%),Headache (26-32%),Arthralgia (7-14%),Pharyngitis (10-12%),Sinusitis (6-11%),Diarrhea (6-7%) 1-10% Depression (5-8%),Dizziness (4-6%),Nervousness (2-5%),Flatulence (6-7%),Vaginitis (5-7%),Leukorrhea (4-7%),Leg cramps (3-7%),Increased cough (4-7%),Pruritus (4-5%) Frequency Not Defined Amenorrhea,Breakthrough bleeding,Corneal curvation change,Melasma,Spotting,Vaginal moniliasis,Weight changes Potentially Fatal: Unopposed replacement therapy in postmenopausal women associated with increased risk of endometrial and breast cancer. Potentially Fatal: Unopposed replacement therapy in postmenopausal women associated with increased risk of endometrial and breast cancer. Interaction: Rifampicin, barbiturates increase rate of metabolism. Potentially Fatal: May reduce the efficacy of anticoagulants.